Autolus Therapeutics (AUTL) Stock Analysis & Winston Score

Autolus Therapeutics is a British biotechnology company that develops cancer treatments using a technology called CAR-T cell therapy. This approach takes a patient's own immune cells, engineers them in a lab to recognize and attack cancer cells, and then puts them back into the patient's body. The company's lead product, Aucatzyl (obecabtagene autoleucel), was approved by the FDA in 2024 to treat a type of blood cancer called B-cell acute lymphoblastic leukemia in adults. Autolus makes money by selling Aucatzyl to hospitals and cancer treatment centers in the United States, where it is currently launching the product commercially. The company is small, with a market cap around $500 million, and it is still spending far more than it earns, which is typical for early-stage biotech firms. The key growth driver is how quickly Aucatzyl gains adoption among oncologists, while the main risk is that the company may need to raise additional cash to fund operations before reaching profitability.